Text Size

Oxidative stress in retinal diseases

Nishimura Y., Hara H., Kondo M., Hong S., Matsugi T.


  • 2017
  • Oxidative Medicine and Cellular Longevity
View publication
  • Therapeutic Area

    Back of the eye (BOTE)

  • Categories

    Disease understanding (epidemiology, diagnosis, QoL, Biomarkers…)

  • Affiliations

    Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University, Graduate School of Medicine, Mie, 514-8507, Japan; Molecular Pharmacology, Department of Biofunctional Evaluation, Gifu Pharmaceutical University, Gifu, 501-1196, Japan; Department of Ophthalmology, Mie University, Graduate School of Medicine, Tsu, Mie, 514-8507, Japan; Department of Ophthalmology, Yonsei University, College of Medicine, Seoul, 03722, South Korea; Non-Clinical Research, Santen Pharmaceutical Co. Ltd., Osaka, 530-8552, Japan

Related Publications

Cost-Effectiveness Analysis of Low-Dose Atropine Eye Drops (0.01%) for the Treatment of Myopia in Children: A United Kingdom Perspective

Shi-van Wielink K., Dahlmann-Noor A., Li J., de Milliano T.W.L., Ernst F., Croci F., Sharma Y., Punekar Y.


Two-year prospective natural history study of EYS-associated retinitis pigmentosa using adaptive optics: the KEYS study

Masakazu H., Akiko M., Midori Y., Elena G.-S., Shohei K., Satoshi Y., Yuki T., Masanao T., Shuhei K., Yasuhiko H., Yasuo K., Kiyoko G.


Prospective natural history and clinical biomarkers of EYS-associated retinopathy in the KEYS study

Taniguchi M, Togashi Y, Yokota S, Hiraoka M, Kitahata S, Nakamura N, Yamamoto M, Mandai M, Gocho K, Toshimori M, Hirami Y, Gomi F, Kurimoto Y, Maeda A.


Can't find what you're looking for?

Contact us

Document number: NP-No product-EMEA-0110
Date of preparation: February 2022